United States · 
What does EcoR1 Capital invest in?
EcoR1 Capital invests most often at Series B and Series A (68% of the rounds on record), in sectors such as Biotech.
EcoR1 Capital highlights
- 01
33 rounds on record
- 02
Mostly Series B and Series A: 68% of its rounds
What they do
We are a San Francisco based biotech-focused investment fund.From their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowth
- Sectors
- Biotech
- Based in
- San Francisco, United States
- Cold pitches
- Accepted
The record
Every round we can evidence, newest first33 appearances
- 2020
1 round
- Jun
- 2019
5 rounds
- Oct
- May
- May
- Mar
- Jan
- 2018
7 rounds
- Oct
- Sept
- Sept
- May
- Mar
- Mar
- Feb
- 2017
5 rounds
- Dec
- Nov
- Nov
- Jul
- Jan
- 2015
9 rounds
- Dec
- Sept
- Aug
- Aug
- Aug
- Jun
- Jun
- Mar
- Mar
- 2014
4 rounds
- Sept
- Sept
- Mar
- Jan
- 2013
1 round
- Dec
- 2010
1 round
- Jan
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration8 named
BBBrian BurkholderDirectoriFiling they signed
CMCary MarrDirectoriFiling they signed
ONOleg NodelmanManager of Biotech Opportunity GP, LLC, General PartneriFiling they signed
SMSarah MarriottChief Operating Officer of Biotech Opportunity GP, LLC, General PartneriFiling they signed
SPScott PerlenChief Financial Officer of Biotech Opportunity GP, LLC, General PartneriFiling they signed
TWTim WoolaverDirectoriFiling they signed
TOTrustee Oleg NodelmanManageriForm ADV
TSTrustee Sarah MarriottMember, CCO, COOiForm ADV
We also hold 14 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$3.4Bassets it managesOct 2026
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Ecor1 Capital, LLC
- SEC number
- CRD 167121
Funds on its Form ADV
3 private funds, $5.0B in gross assets · filed Oct 2024
Hedge 2Venture 1
- EcoR1 Capital Fund Qualified, L.P.Hedge324 investors$4.6B
- EcoR1 Capital Fund, L.P.Hedge87 investors$312M
- EcoR1 Venture Opportunity Fund, L.P.Venture59 investors$85M
What they claim to have backed
From their own portfolio page (on their website)
27 of 42 we have independently watched raise
AjaxtherapeuticsAkouosAktisoncologyAllovirAnaginArcusbioAtrecaAtyrpharmaCellaresDenalitherapeuticsEditasmedicineElevateEpikastFlex-pharmaFreenomeGossamerbioKronosbioKuraoncologyMetacrineNeurogeneNuvationbioOricpharmaPellepharmPrevailtherapeuticsScholarrockShattucklabsUnitybiotechnologyActiobiosciencesArtivabioAtarabioAviditynanoCentessaClementiapharmaCodiakbioCollegiumpharmaKezarbioKindredbioKumquatbiosciencesMorphimmuneNabrivaNeogeneTerremotobio
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.